Tempo Scan Pacific Tbk

tspc

+0.51%

Overview

TSPC Overview

PT Tempo Scan Pacific Tbk is an Indonesia-based company engaged in the industry of pharmaceuticals, consumer products and cosmetics. The Company’s segments include Pharmaceuticals, Consumer Products and Cosmetics, and Distribution Services. The Pharmaceuticals segment conducts marketing of consumer health products consisting of over the counter; vitamin, mineral and supplement (VMS) and beverage products; nutritional products and herbal products; and prescription medicine products. The Consumer Products and Cosmetics segment markets and distributes own branded products as well as licensed cosmetics products. The Distribution Services segment distributes products to customers. The segment serves customers from various sales branches throughout Indonesia, covering pharma, modern trade, and general trade channels. It also markets and distributes its products overseas through its international business units. Its business network covers about 220 locations that consist of 47 branches.

5101520ValueCompetitiveFutureFinancialsDividend
Exchange
Indonesia Stock Exchange

Symbol: TSPC

Main
Market Cap.
IDR 8.97Trillion

~$551.04M USD

Industry
Pharmaceuticals
Sub-Industry
Pharmaceuticals
Sector
Healthcare

Valuation

TSPC Valuation Metrics

1,980

IDR
+0.5%

Closing Price on 2024-06-14

Price to Equity

8.83

P/E

At 8.83x P/E TTM, TSPC.JK is trading in line with its peers in the Pharmaceuticals & Health Care Research sector.

Price to Book

1.11

P/B

At 1.11x P/B TTM, TSPC.JK is trading in line with its peers in the Pharmaceuticals & Health Care Research sector.

Price to Sales

0.67

P/S

At 0.67x P/S TTM, TSPC.JK is trading at a discount to its peers in the Pharmaceuticals & Health Care Research sector.

Valuing Tempo Scan Pacific Tbk based on its trailing twelve months (TTM) valuation metrics against its peers in the Pharmaceuticals & Health Care Research sector

Historical Price to Earnings

Other Valuation Metrics

Valuing Tempo Scan Pacific Tbk relative to other stocks in the Pharmaceuticals & Health Care Research sector

Price/Cash Flow
5.92x
Price/Forward Earnings
-
Enterprise Value/Revenue
0.44x
Enterprise Value/EBITDA
3.40x
PEG Ratio
-0.31x

Analyst Ratings

No analyst ratings available yet.

Last closing: IDR1,9802024-06-14
IDR 3,816.93

Considerably Higher Intrinsic Value: Analyst's intrinsic value is of TSPC is IDR3,817, which is 94% higher than TSPC's last closing price of IDR1,980 (as of 2024-06-14).

Valuation Recap of TSPC stock
WeightNotesScore
High
The P/E ratio is calculated by dividing the market price of a company's stock by its earnings per share (EPS). It is a key tool for investors and analysts to assess whether a stock is overvalued, undervalued, or fairly valued. A P/E ratio of 8.83x is above the ID market average of 8.07x and is trading at a discount to peers in the Pharmaceuticals & Health Care Research sector (9.96x).

High
The P/B ratio is calculated by dividing the market price of a company's stock by its book value per share (BVPS). It measures the company's stock value relative to its assets minus liabilities. A P/B ratio of 1.11x is similar to the peers average of 1.17x in the Pharmaceuticals & Health Care Research sector.

Medium
The P/S ratio is calculated by dividing the market price of a company's stock by its sales per share. It measures the company's stock value relative to its sales. A P/S ratio of 0.67x is similar to the peers average of 0.80x in the Pharmaceuticals & Health Care Research sector. When considered alongside the Forward Price/Earnings ratio, they serve to illustrate investors' expectations of TSPC's valuation relative to its current sales and future earnings growth.

Low
The Price/Cash Flow ratio (P/CF) is calculated by dividing the market price of a company's stock by its cash flow per share. It measures the company's stock value relative to its cash flow, and is sometimes said to be a more objective measure of a company's value because cash flows cannot be manipulated as easily as earnings, which considers non-cash items such as depreciation and amortization. TSPC's P/CF ratio of 5.92x is considered healthy by analysts.

Low
The Enterprise Value/Revenue ratio (EV/R) is calculated by dividing the enterprise value of a company by its revenue. It measures the company's enterprise value relative to its revenue. It is an indicator of how much it costs to buy the company's revenue; the lower the ratio, the cheaper the company's revenue. TSPC's EV/R ratio of 0.44x is considered extremely underpriced by the market The average EV/R ratio for the Pharmaceuticals & Health Care Research sector is 1.10x.

Medium
Considerably Higher Intrinsic Value: Analyst's intrinsic value is of TSPC is IDR 3,816.93, which is 94% higher than TSPC's last closing price of IDR 1,980.00.

Peers

TSPC Peers and Comparison

Peer Companies

Supertype Fuzzy Search
SymbolCompany Name
Market Cap
(in Trillion IDR)
Total Assets
(in Trillion IDR)
Total Revenue
(in Trillion IDR)
Profit and Loss
(in Trillion IDR)
P/E
P/B
KLBFKalbe Farma Tbk72.39T28.96T 30.94T 2.87T 25.243.23
MIKAPT Mitra Keluarga Karyasehat Tbk.41.72T7.81T 4.48T 0.97T 42.826.83
SILOPT Siloam International Hospitals Tbk.33.75T11.42T 11.56T 0.98T 34.614.27
SRAJSejahteraraya Anugrahjaya Tbk26.40T5.62T 2.71T -0.02T -1327.5114.19
SIDOPT Industri Jamu Dan Farmasi Sido Muncul Tbk22.20T4.25T 3.71T 1.04T 21.335.85
HEALPT Medikaloka Hermina Tbk.20.03T9.20T 6.14T 0.52T 38.564.80
TSPCTempo Scan Pacific Tbk8.97T11.93T 13.33T 1.02T 8.831.11
PRAYPT Famon Awal Bros Sedaya Tbk8.86T4.81T 1.93T 0.21T 43.073.08
SOHOPT Soho Global Health Tbk8.63T5.13T 8.58T 0.44T 19.583.42
OMEDPT Jayamas Medica Industri Tbk5.38T2.65T 1.77T 0.27T 20.212.36
Competitiveness Recap of TSPC stock
WeightNotesScore
High
At a market cap of IDR 8,974.17 billion, TSPC.JK ranks 7 in Market Cap out of 10 companies in the Healthcare sector.

High
At a PE of 8.83, TSPC.JK ranks 9 out of 10 companies in the Healthcare sector for P/E value. The average PE is -107.33 (unadjusted). A high P/E ratio often indicates higher growth expectation, or other qualitative factors that led investors to believe that the company has a defensible competitive advantage compared to its peers in Healthcare. In this regard, it trails behind sector leaders such as PT Famon Awal Bros Sedaya Tbk (43.07) in the Healthcare sector.

Medium
At a PE of 8.83, TSPC.JK is trading at a lower PE than that of its subsector peers in Pharmaceuticals & Health Care Research (median of 9.96). A lower P/E value presents a potential value opportunity, but it might also indicate that the company is facing headwinds in its business.

Medium
At a revenue of IDR 13.33 trillion, TSPC.JK ranks 2 in Revenue out of 10 companies in the Healthcare sector.

Medium
At a profit of IDR 1.02 trillion, TSPC.JK ranks 3 in Profit out of 10 companies in the Healthcare sector.

Future

Future Growth of TSPC

Growth Forecasts

No data available

Sector Benchmark

Pharmaceuticals & Health Care Research companies in Indonesia are growing at a projected rate of 14.72% against the IDX average of +13.1%.

Pharmaceuticals & Health Care Research sector overview
No data is available for TSPC at the moment.
Future growth prospect of TSPC
WeightNotesScore
High
TSPC's projected growth rate of 14.72% is above the ID market average of 13.14%.

High
The Pharmaceuticals & Health Care Research sub-sector is projected to grow revenue by 15.82% in 2025. This number is higher than the previous year 2024's growth rate of 7.04%. This bodes well for TSPC's revenue growth prospects in the next 2 years.

Medium
The Pharmaceuticals & Health Care Research sub-sector is projected to increase earnings by 24.87% in 2025. This number is higher than the previous year 2024's EPS growth of 12.80%. This bodes well for TSPC's earnings growth prospects in the next 2 years.

Medium
TSPC and its peers in the Pharmaceuticals & Health Care Research sub-sector belongs to the Healthcare sector. Companies in the Healthcare sector are projected to have a fruitful year heading into 2025. Specifically, earnings are projected to increase by 22.74% in 2025 while revenue growth is projected to increase by 20.17%. These macroeconomic trends will likely be a tailwind for TSPC's earnings growth prospects in the next 2 years.

Loading...
Loading...

Management

Executive Management

President Director

I Made Dharma Wijaya15.2 years

Vice President Director

Diana Wirawan15.4 years
Linda Lukitasari
Director
Shania
Director
Rorita Lim
Director
Josep Ismanto
Director
Lie Yung Yung
Director
Aviaska Diah Respati H
Director
NamePositionShares%
Aviaska Diah Respati HDirector780,0000.02
Diana WirawanVice President Director1,045,5000.02
Hartaty Susanto Commissioner499,500< 0.01
I Made Dharma WijayaPresident Director454,000< 0.01
Josep IsmantoDirector314,800< 0.01
Lie Yung YungDirector314,000< 0.01
Linda LukitasariDirector410,000< 0.01
Liza Prasodjo Director679,0000.02
Rorita LimDirector404,000< 0.01
ShaniaDirector479,000< 0.01
Expressed in millions IDR, unless otherwise stated

Ownership

TSPC Ownership

NameNumber of SharesOwnership (%)Value
Pt Bogamulia Nagadi3,883,754,71886.127,689.83B
Public (Scripless)604,262,68213.41,196.44B
Public (Scrip)16,467,1000.3532.60B
Liza Prasodjo 679,0000.021.34B
Diana Wirawan1,045,5000.022.07B
Aviaska Diah Respati H780,0000.021.54B
Rorita Lim404,0000.010.80B
Shania479,0000.010.95B
Hartaty Susanto 499,5000.010.99B
I Made Dharma Wijaya454,0000.010.90B
Josep Ismanto314,8000.010.62B
Lie Yung Yung314,0000.010.62B
Linda Lukitasari410,0000.010.81B

Largest Institutional Buy

Acadian Asset Management LLC
Bought 31-01-2024
+397,500 shares
Dimensional Fund Advisors
Bought 31-01-2024
+89,600 shares

Largest Institutional Sell

FIL Fund Management Limited
Sold 31-01-2024
-17,067,315 shares
FIL Investments (Japan) Limited
Sold 31-01-2024
-16,017,500 shares
Fidelity Investments Canada ULC
Sold 31-01-2024
-4,428,541 shares

Institutional Transactions

Tracking institutional transactions buying / selling of TSPC stock

    Sectors, Indonesia's Financial Data Layer

    We hate spam as much as you do. We do not resell your data.

    Email us at sectors@supertype.ai for enquiries on using Sectors for your business or organization.

    © 2024 Supertype Pte. Ltd.
    (and subsidiary PT. Supertype Teknologi Nusantara)